Human Immunopathogenesis of Severe Acute Respiratory Syndrome (SARS)

Overview

Journal Virus Res

Specialty Microbiology

Date 2007 Mar 22

PMID 17374415

Citations 220

Authors

Mark J Cameron

Jesus F Bermejo-Martin

Ali Danesh

Matthew P Muller

David J Kelvin

Affiliations

Soon will be listed here.

Abstract

Progressive immune-associated injury is a hallmark of severe acute respiratory syndrome (SARS). Viral evasion of innate immunity, hypercytokinemia and systemic immunopathology in the SARS coronavirus (SARS CoV) infected host have been suggested as possible mechanisms for the cause of severe pathology and morbidity in SARS patients. The molecular and cellular basis for how SARS CoV impacts the host immune system resulting in severe SARS, however, has not been elucidated. The variable clinical course of SARS may be the result of complex programs of host responses against the infectious agent. Therefore, the systematic analysis of innate and adaptive immune responses to SARS CoV is imperative in building as complete an immunological model as possible of host immunity and inflammatory responses during illness. Here we review recent advances in SARS immunopathogenesis research and present a summary of our findings regarding host responses in SARS patients. We contend that dysregulated type I and II interferon (IFN) responses during SARS may culminate in a failure of the switch from hyper-innate immunity to protective adaptive immune responses in the human host.

Citing Articles

SARS-CoV-2 specific adaptations in N protein inhibit NF-κB activation and alter pathogenesis.

Guo X, Yang S, Cai Z, Zhu S, Wang H, Liu Q J Cell Biol. 2024; 224(1).

PMID: 39680116 PMC: 11648720. DOI: 10.1083/jcb.202404131.

Advanced biomaterials for regenerative medicine and their possible therapeutic significance in treating COVID-19: a critical overview.

Sarangi A, Salem M, Younus M, El-Haroun H, Mahal A, Tripathy L Int J Surg. 2024; 110(12):7508-7527.

PMID: 39411890 PMC: 11634172. DOI: 10.1097/JS9.0000000000002110.

Interaction of toll-like receptors and ACE-2 with different variants of SARS-CoV-2: A computational analysis.

Zahmatkesh A, Salmasi E, Gholizadeh R Bioimpacts. 2024; 14(4):30150.

PMID: 39104618 PMC: 11298020. DOI: 10.34172/bi.2024.30150.

Coronavirus disease 2019-related myocarditis genes contribute to ECMO prognosis.

Yan A, Zhang R, Feng C, Feng J BMC Cardiovasc Disord. 2024; 24(1):375.

PMID: 39026189 PMC: 11264513. DOI: 10.1186/s12872-024-04032-5.

Curcumin as an antiviral agent and immune-inflammatory modulator in COVID-19: A scientometric analysis.

Liu K, Zhu Y, Cao X, Liu Y, Ying R, Huang Q Heliyon. 2023; 9(11):e21648.

PMID: 38027776 PMC: 10661356. DOI: 10.1016/j.heliyon.2023.e21648.

References

Huang K, Su I, Theron M, Wu Y, Lai S, Liu C . An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2004; 75(2):185-94. PMC: 7166886. DOI: 10.1002/jmv.20255. View

de Veer M, Holko M, Frevel M, Walker E, Der S, Paranjape J . Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001; 69(6):912-20. View

Takaoka A, Yanai H . Interferon signalling network in innate defence. Cell Microbiol. 2006; 8(6):907-22. DOI: 10.1111/j.1462-5822.2006.00716.x. View

Rainer T, Cameron P, Smit D, Ong K, Hung A, Nin D . Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. BMJ. 2003; 326(7403):1354-8. PMC: 162123. DOI: 10.1136/bmj.326.7403.1354. View

Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2):631-7. PMC: 7167720. DOI: 10.1002/path.1570. View

Fowler R, Lapinsky S, Hallett D, Detsky A, Sibbald W, Slutsky A . Critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290(3):367-73. DOI: 10.1001/jama.290.3.367. View

Salto-Tellez M, Tan E, Lim B . ARDS in SARS: cytokine mediators and treatment implications. Cytokine. 2004; 29(2):92-4. PMC: 7128468. DOI: 10.1016/j.cyto.2004.09.002. View

Nicholls J, Poon L, Lee K, Ng W, Lai S, Leung C . Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003; 361(9371):1773-8. PMC: 7112492. DOI: 10.1016/s0140-6736(03)13413-7. View

Wong C, Lam C, Wu A, Ip W, Lee N, Chan I . Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136(1):95-103. PMC: 1808997. DOI: 10.1111/j.1365-2249.2004.02415.x. View

10.

Reghunathan R, Jayapal M, Hsu L, Chng H, Tai D, Leung B . Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol. 2005; 6:2. PMC: 546205. DOI: 10.1186/1471-2172-6-2. View

11.

Farcas G, Poutanen S, Mazzulli T, Willey B, Butany J, Asa S . Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis. 2004; 191(2):193-7. PMC: 7109982. DOI: 10.1086/426870. View

12.

Wong R, Wu A, To K, Lee N, Lam C, Wong C . Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003; 326(7403):1358-62. PMC: 162124. DOI: 10.1136/bmj.326.7403.1358. View

13.

Castilletti C, Bordi L, Lalle E, Rozera G, Poccia F, Agrati C . Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. Virology. 2005; 341(1):163-9. PMC: 7111739. DOI: 10.1016/j.virol.2005.07.015. View

14.

Hwang D, Chamberlain D, Poutanen S, Low D, Asa S, Butany J . Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2004; 18(1):1-10. PMC: 7100506. DOI: 10.1038/modpathol.3800247. View

15.

Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J . Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005; 171(8):850-7. DOI: 10.1164/rccm.200407-857OC. View

16.

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

17.

Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

18.

Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G . A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1986-94. DOI: 10.1056/NEJMoa030685. View

19.

Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View

20.

Chien J, Hsueh P, Cheng W, Yu C, Yang P . Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology. 2006; 11(6):715-22. PMC: 7192207. DOI: 10.1111/j.1440-1843.2006.00942.x. View